Finding success in failure: using latent profile analysis to examine heterogeneity in psychosocial functioning among heavy drinkers following treatment
- PMID: 27367263
- PMCID: PMC5218991
- DOI: 10.1111/add.13518
Finding success in failure: using latent profile analysis to examine heterogeneity in psychosocial functioning among heavy drinkers following treatment
Abstract
Aims: To estimate differences in post-treatment psychosocial functioning among treatment 'failures' (i.e. heavy drinkers, defined as 4+/5+ drinks for women/men) from two large multi-site clinical trials and to compare these levels of functioning to those of the purported treatment 'successes' (i.e. non-heavy drinkers).
Design: Separate latent profile analyses of data from two of the largest alcohol clinical trials conducted in the United States, COMBINE (Combined Pharmacotherapies and Behavioral Interventions) and Project MATCH (Matching Alcoholism Treatments to Client Heterogeneity), comparing psychosocial outcomes across derived classes of heterogeneous treatment responders.
Setting: Eleven US academic sites in COMBINE, 27 US treatment sites local to nine research sites in Project MATCH.
Participants: A total of 962 individuals in COMBINE (69% male, 77% white, mean age: 44 years) treated January 2001 to January 2004 and 1528 individuals in Project MATCH (75% male, 80% white, mean age: 40 years) treated April 1991 to September 1994.
Measurements: In COMBINE, we analyzed health, quality of life, mental health symptoms and alcohol consequences 12 months post-baseline. In Project MATCH, we examined social functioning, mental health symptoms and alcohol consequences 15 months post-baseline.
Findings: Latent profile analysis of measures of functioning in both samples supported a three-profile solution for the group of treatment 'failures', characterized by high-, average- and low-functioning individuals. The high-functioning treatment 'failures' generally performed better across measures of psychosocial functioning at follow-up than participants designated treatment 'successes' by virtue of being abstainers or light drinkers.
Conclusions: Current United States Food and Drug Administration guidance to use heavy drinking as indicative of treatment 'failure' fails to take into account substantial psychosocial improvements made by individuals who continue occasionally to drink heavily post-treatment.
Keywords: Binge drinking; heavy drinking; latent profile analysis; person-centered analysis; psychosocial functioning; treatment failure.
© 2016 Society for the Study of Addiction.
Figures


Comment in
-
Commentary on Wilson et al. (2016): The meaning of success in failure.Addiction. 2016 Dec;111(12):2155-2156. doi: 10.1111/add.13541. Addiction. 2016. PMID: 28075534 No abstract available.
Similar articles
-
Reconsidering alcohol treatment non-responders: psychosocial functioning among heavy drinkers 3 years following treatment.Addiction. 2021 May;116(5):1262-1269. doi: 10.1111/add.15280. Epub 2020 Dec 18. Addiction. 2021. PMID: 33009685 Free PMC article. Clinical Trial.
-
Profiles of recovery from alcohol use disorder at three years following treatment: can the definition of recovery be extended to include high functioning heavy drinkers?Addiction. 2019 Jan;114(1):69-80. doi: 10.1111/add.14403. Epub 2018 Aug 24. Addiction. 2019. PMID: 30063267 Free PMC article.
-
Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.Addiction. 2017 Dec;112(12):2112-2121. doi: 10.1111/add.13870. Epub 2017 Jun 26. Addiction. 2017. PMID: 28511286 Free PMC article.
-
Abstinence and low risk drinking during treatment: Association with psychosocial functioning, alcohol use, and alcohol problems 3 years following treatment.Psychol Addict Behav. 2018 Sep;32(6):639-646. doi: 10.1037/adb0000381. Epub 2018 Aug 30. Psychol Addict Behav. 2018. PMID: 30160499 Free PMC article. Clinical Trial.
-
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.Addiction. 2020 Sep;115(9):1668-1680. doi: 10.1111/add.15011. Epub 2020 Mar 10. Addiction. 2020. PMID: 32056311 Free PMC article. Clinical Trial.
Cited by
-
Factors associated with quality of life trajectories among inpatients treated for alcohol use disorders: A prospective cohort study.Addict Behav Rep. 2020 May 20;12:100285. doi: 10.1016/j.abrep.2020.100285. eCollection 2020 Dec. Addict Behav Rep. 2020. PMID: 32637561 Free PMC article.
-
Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population.Drug Alcohol Depend. 2019 Apr 1;197:228-235. doi: 10.1016/j.drugalcdep.2019.01.009. Epub 2019 Feb 14. Drug Alcohol Depend. 2019. PMID: 30852375 Free PMC article.
-
Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder.Alcohol Clin Exp Res. 2018 Sep;42(9):1612-1622. doi: 10.1111/acer.13829. Epub 2018 Jul 30. Alcohol Clin Exp Res. 2018. PMID: 29969156 Free PMC article. Review.
-
Prevention, screening, and treatment for heavy drinking and alcohol use disorder.Lancet Psychiatry. 2019 Dec;6(12):1054-1067. doi: 10.1016/S2215-0366(19)30213-5. Epub 2019 Oct 17. Lancet Psychiatry. 2019. PMID: 31630982 Free PMC article. Review.
-
Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population.Alcohol Clin Exp Res. 2018 Nov;42(11):2256-2265. doi: 10.1111/acer.13884. Epub 2018 Oct 3. Alcohol Clin Exp Res. 2018. PMID: 30204248 Free PMC article.
References
-
- Maisto SA, Clifford PR, Stout RL, Davis CM. Moderate drinking in the first year after treatment as a predictor of three-year outcomes. J Stud Alcohol Drugs. 2007;68(3):419–427. - PubMed
-
- Administration F and D. Medical Review of Vivitrol: 21–897. Rockville, MD: 2006.
-
- Administration F and D. Alcoholism: Developing Drugs for Treatment (No. PDA D-0152-001) Silver Spring, MD: Food and Drug Administration; 2015.
-
- European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. 2010 Feb;:1–17.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous